Revolution Medicines (RVMD) News Today

First Turn Management LLC bought a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 329,519 shares of the company's stock, va

Nicholas Investment Partners LP purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 158,132 shares of the company's stock, valued at approximately $6,137,000. Ni

Great Lakes Advisors LLC lowered its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 58.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 120,867 shares of the company's stock after sellin

Candriam S.C.A. cut its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 5.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 554,334 shares of the company's stock after selli

Bank of New York Mellon Corp boosted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 21.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 645,253 shares of the company's stock af

Raymond James & Associates raised its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 196.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 74,370 shares of the company's s

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) have received an average recommendation of "Buy" from the twelve research firms that are currently covering the company, Marketbeat.com reports. Eleven research analysts have rated the stock with a buy recommendation and one has

Legato Capital Management LLC acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,199 shares of the company's stock, valued at app

Revolution Medicines (NASDAQ:RVMD) Trading Up 4.7%

China Universal Asset Management Co. Ltd. cut its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 38.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,383 shares of the company

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Equities researchers at HC Wainwright cut their Q3 2024 earnings estimates for Revolution Medicines in a report released on Monday, August 12th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Stock analysts at Leerink Partnrs reduced their Q3 2024 EPS estimates for Revolution Medicines in a research report issued on Wednesday, August 7th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings per shar

Revolution Medicines (NASDAQ:RVMD - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The company had revenue of $1.00 million during the quarter, compared to the consensus estimate of $0.81 million. The firm's quarterly revenue was down 73.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.92) earnings per share.

JPMorgan Chase & Co. dropped their price objective on Revolution Medicines from $55.00 to $54.00 and set an "overweight" rating for the company in a research report on Thursday.

Wedbush reissued an "outperform" rating and issued a $59.00 price objective on shares of Revolution Medicines in a research note on Thursday.

Revolution Medicines (NASDAQ:RVMD) Shares Gap Down Following Weak Earnings

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) have been given a consensus recommendation of "Buy" by the twelve ratings firms that are currently covering the company, MarketBeat.com reports. Eleven investment analysts have rated the stock with a buy recommendation and one ha

Revolution Medicines (NASDAQ:RVMD) will be releasing earnings after the market closes on Wednesday, August 7, Zacks reports.

Janus Henderson Group PLC raised its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 77.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,912,119 shares of the company's sto

Sei Investments Co. bought a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 16,371 shares of the company's stock, valued at appro

Paloma Partners Management Co bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,545 shares of the

Bellevue Group AG reduced its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 0.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,073,600 shares of the company's stock after selling 17,400 shares during the quart

Vanguard Group Inc. raised its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 0.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,757,112 shares of the company's stock aft

Seven Eight Capital LP bought a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 68,494 shares of the company's stock, valued at approximately

Barclays lifted their price target on shares of Revolution Medicines from $52.00 to $54.00 and gave the company an "overweight" rating in a research report on Thursday.

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Investment analysts at Wedbush reduced their Q2 2024 earnings per share (EPS) estimates for shares of Revolution Medicines in a report released on Monday, July 15th. Wedbush analyst R. Driscoll now forecasts that the company will post earni

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Mark A. Goldsmith sold 25,000 shares of the company's stock in a transaction on Friday, July 12th. The shares were sold at an average price of $45.05, for a total value of $1,126,250.00. Following the completion of the transaction, the insider now directly owns 311,885 shares in the company, valued at approximately $14,050,419.25. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Oppenheimer increased their target price on shares of Revolution Medicines from $45.00 to $55.00 and gave the company an "outperform" rating in a research report on Tuesday.

Mirae Asset Global Investments Co. Ltd. lessened its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 36.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,059 shares of the company's stock

Susquehanna Fundamental Investments LLC purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 206,513 shares of the company's stock, v

Duality Advisers LP purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 25,623 shares of the company's stock, valued at approximately $826,000. Other large

Revolution Medicines (NASDAQ:RVMD) Reaches New 52-Week High at $42.50

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) General Counsel Jeff Cislini sold 2,000 shares of the company's stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $38.47, for a total transaction of $76,940.00. Following the transaction, the general counsel now owns 49,487 shares of the company's stock, valued at $1,903,764.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vanguard Group Inc. grew its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 51.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,634,391 shares of the company's stock after